{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T12:02:08Z","timestamp":1784721728079,"version":"3.55.0"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>\n                    This case report describes a 57-year-old male patient who sought medical attention due to severe pneumonia and respiratory failure. The initial empirical antibiotic treatment was ineffective. Bronchoscopy and lung alveolar lavage fluid culture confirmed a case of\n                    <jats:italic>Aspergillus fumigatus<\/jats:italic>\n                    infection. Antifungal treatment with the conventional dose of VRZ was administered, but the patient continued to have a fever, and the trough concentration of VRZ detected exceeded the upper limit of the normal range. The clinical pharmacist discovered that the blood sample collected for TDM of this patient was taken 2\u202fh after medication administration rather than the trough concentration. Based on the data of Aspergillus resistance monitoring network and the phenomenon that the patient\u2019s blood drug concentration did not match the clinical efficacy, the clinical pharmacist recommended increasing the dose of VRZ and suggested re-testing the trough concentration of VRZ after the blood drug concentration reached a steady state. The patient rapidly achieved a fever reduction and was ultimately cured. The re-tested blood drug concentration was within the normal range. This case demonstrates that clinical pharmacists play an indispensable role in the quality control of therapeutic drug monitoring. They will standardize the sampling time, interpret the test results in combination with the clinical condition, adjust the dose based on pharmacokinetic principles, strengthen interdisciplinary cooperation, and optimize antifungal treatment.\n                  <\/jats:p>","DOI":"10.3389\/fmed.2026.1878131","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T11:12:03Z","timestamp":1784718723000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Voriconazole pseudotoxicity: a case report highlighting the importance of sampling timing in TDM interpretation by clinical pharmacists"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiao-Ming","family":"Deng","sequence":"first","affiliation":[{"name":"Department of Pharmacy, The First People's Hospital of Wuyi County","place":["Jinhua, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The First People's Hospital of Wuyi County","place":["Jinhua, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Qi","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Medical School, Hangzhou City University","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Jie","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First People's Hospital of Wuyi County","place":["Jinhua, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Li","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital","place":["Quzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-Yu","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital","place":["Quzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1124\/dmd.31.5.540","article-title":"Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole","volume":"31","author":"Hyland","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1002\/cpt.583","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy","volume":"102","author":"Moriyama","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ijantimicag.2015.12.003","article-title":"Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections","volume":"47","author":"Lamoureux","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1097\/FTD.0000000000000561","article-title":"Individualized medication of voriconazole: a practice guideline of the division of therapeutic drug monitoring, Chinese pharmacological society","volume":"40","author":"Chen","year":"2018","journal-title":"Ther Drug Monit"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"10507","DOI":"10.2147\/DDDT.S560753","article-title":"The predictive value of initial trough concentration of voriconazole and procalcitonin in hepatotoxic adverse events","volume":"19","author":"Chen","year":"2025","journal-title":"Drug Des Devel Ther"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1097\/FTD.0000000000000901","article-title":"Review of the preanalytical errors that impact therapeutic drug monitoring","volume":"43","author":"Peck Palmer","year":"2021","journal-title":"Ther Drug Monit"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.jsps.2014.11.005","article-title":"Sampling time and indications appropriateness for therapeutically monitored drugs at a teaching university hospital in Oman","volume":"23","author":"Al Za'abi","year":"2015","journal-title":"Saudi Pharm J"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1046\/j.1365-2125.2003.01993.x","article-title":"Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety","volume":"56","author":"Purkins","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13054-022-04050-9","article-title":"Expert clinical pharmacological advice may make an antimicrobial TDM program for emerging candidates more clinically useful in tailoring therapy of critically ill patients","volume":"26","author":"Gatti","year":"2022","journal-title":"Crit Care"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1086\/588844","article-title":"Hallucinations during voriconazole therapy","volume":"47","author":"Zonios","year":"2008","journal-title":"Clin Infect Dis"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1616061","DOI":"10.3389\/fphar.2025.1616061","article-title":"Unexpected voriconazole toxicity due to nirmatrelvir\/ritonavir: a case report on drug-drug interaction and the role of therapeutic drug monitoring","volume":"16","author":"L\u00f3pez-Hern\u00e1ndez","year":"2025","journal-title":"Front Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"106711","DOI":"10.1016\/j.ijantimicag.2023.106711","article-title":"Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: a multicentre, prospective, cluster randomised, crossover clinical trial","volume":"61","author":"Veringa","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1133662","DOI":"10.3389\/fcvm.2023.1133662","article-title":"Escitalopram-induced sinus bradycardia in coronary heart disease combined with depression: a case report and review of literature","volume":"10","author":"Li","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/ddr.22025","article-title":"Treatment strategies and pharmacist-led medication management for Helicobacter pylori infection","volume":"84","author":"Wang","year":"2023","journal-title":"Drug Dev Res"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2147\/DDDT.S286315","article-title":"Chronic obstructive pulmonary disease treatment and pharmacist-led medication management","volume":"15","author":"Li","year":"2021","journal-title":"Drug Des Devel Ther"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1878131\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T11:12:04Z","timestamp":1784718724000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1878131\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":17,"alternative-id":["10.3389\/fmed.2026.1878131"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1878131","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"article-number":"1878131"}}